State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.
Oncol Rep. 2020 Aug;44(2):438-448. doi: 10.3892/or.2020.7623. Epub 2020 May 25.
Recent studies have revealed the oncogenic role of notch reporter 3 (NOTCH3) in ovarian cancer (OC). However, the possible regulators and mechanisms underlying notch receptor 3 (NOTCH3)‑mediated behaviors in OC remain to be completely investigated. In the present study, we aimed to identify regulators of NOTCH3 and their interactions underlying the pathogenesis of OC. Bioinformatics analysis and luciferase reporter assay were used to identify potential regulatory miRNAs and lncRNAs of NOTCH3 in OC. Several in vivo and in vitro assays were performed to evaluate their effects on the proliferative ability mediated by NOTCH3. We identified microRNA‑1299 (miR‑1299) as a novel negative regulator of NOTCH3. miR‑1299 was downregulated in OC and was found to be considerably correlated with tumor differentiation. Upregulation of miR‑1299 inhibited cell proliferation, colony formation, and 5‑ethynyl‑2'‑deoxyuridine (EdU) incorporation, as well as induced cell cycle arrest in the G0G1 phase in OC cells. Overexpression of miR‑1299 in xenograft mouse models suppressed tumor growth in vivo. The lncRNA taurine upregulated gene 1 (TUG1), acting as a sponge of miR‑1299, was found to upregulate NOTCH3 expression and promote cell proliferation in OC through the competing endogenous RNA mechanism. In addition, TUG1 was found to be a potential downstream target of NOTCH3, forming a miR‑1299/NOTCH3/TUG1 feedback loop in the development of OC. Collectively, our findings improve the understanding of NOTCH3‑mediated regulation in OC pathogenesis and facilitate the development of miRNA‑ and lncRNA‑directed diagnostics and therapeutics against this disease.
最近的研究揭示了 Notch 报告基因 3(NOTCH3)在卵巢癌(OC)中的致癌作用。然而,NOTCH 受体 3(NOTCH3)介导的 OC 行为的可能调节剂和机制仍有待完全研究。在本研究中,我们旨在确定 NOTCH3 的调节剂及其在 OC 发病机制中的相互作用。生物信息学分析和荧光素酶报告基因检测用于鉴定 OC 中 NOTCH3 的潜在调节 miRNA 和 lncRNA。进行了几种体内和体外实验来评估它们对 NOTCH3 介导的增殖能力的影响。我们确定 microRNA-1299(miR-1299)是 NOTCH3 的一种新型负调节剂。miR-1299 在 OC 中下调,并且与肿瘤分化密切相关。miR-1299 的上调抑制 OC 细胞的增殖、集落形成和 5-乙炔基-2'-脱氧尿苷(EdU)掺入,并诱导细胞周期停滞在 G0/G1 期。在异种移植小鼠模型中过表达 miR-1299 抑制体内肿瘤生长。作为 miR-1299 海绵的 lncRNA 牛磺酸上调基因 1(TUG1)被发现通过竞争性内源性 RNA 机制上调 NOTCH3 表达并促进 OC 细胞增殖。此外,TUG1 被发现是 NOTCH3 的潜在下游靶标,在 OC 的发生发展中形成 miR-1299/NOTCH3/TUG1 反馈环。总之,我们的研究结果提高了对 NOTCH3 介导的 OC 发病机制中调控作用的理解,并促进了针对该疾病的 miRNA 和 lncRNA 导向的诊断和治疗的发展。